our science
Our lead program
Eikonizo’s Platform Targets HDAC6
Eikonizo is developing brain-penetrant, small molecule, selective histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative disease, including amyotrophic lateral sclerosis and Alzheimer’s disease.
Therapeutic & Companion Imaging Agent
Our approach combines highly brain-penetrant small molecules with companion PET imaging agents to de-risk and hasten clinical development
Therapeutic
Development
Our brain penetrant small molecules inhibit HDAC6, an enzyme that modifies key proteins involved in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD)
Therapeutic
Development
Inhibiting HDAC6 will preserve axonal transport and stop or slow the progression of ALS and also help neuron health in other neurodegenerative disease. Emerging data suggest HDAC6 inhibition can also prevent pathological tau phosphorylation and downstream aggregation (tangles) in AD and ‘chemo-brain’.
Companion HDAC6 PET Tool for Target Engagement
We establish in vivo target engagement early, both pre-clinically and clinically, by utilizing Eikonizo’s proprietary HDAC6 positron emission tomography (PET) imaging tool.
Companion HDAC6 PET Tool for Target Engagement
We have validated our HDAC6 PET tool for human use. Our approach de-risks and hastens clinical development by supporting direct visualization and quantitation of target engagement in the brain of living patients.
Therapeutic Hypothesis
Illustrations of how HDAC6 inhibitor treatment will preserve axonal transport and prevent tau aggregation to stop or slow the progression of ALS and AD
Supporting
Literature
Extensive data from multiple research groups support Eikonizo’s approach for using HDAC6 inhibitors as a disease-modifying therapeutic for neurodegeneration in ALS and AD